Literature DB >> 1696618

Monoclonal antibodies allow precipitation of esterasic but not peptidasic activities associated with butyrylcholinesterase.

F Checler1, J Grassi, P Masson, J P Vincent.   

Abstract

Commercially available and affinity-purified butyrylcholinesterases isolated from human serum were examined for their esterasic activity and their ability to hydrolyze various neuropeptides, including neurotensin, substance P, and leucine-enkephalin. The three pools that displayed the lowest esterasic activities were shown to hydrolyze neurotensin with the same HPLC degradative pattern. By contrast, noticeable qualitative and quantitative discrepancies were observed when hydrolyses of substance P and leucine-enkephalin by these three butyrylcholinesterase pools were studied. The pool that exhibited the highest esterasic activity appeared to be homogeneously constituted by 90- and 180-kDa protein bands by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis and was totally unable to hydrolyze these three neuropeptides. This suggested that the three other butyrylcholinesterase preparations could be contaminated by exogenous peptidases. This was confirmed by means of three distinct monoclonal antibodies directed toward human serum butyrylcholinesterase. The three IgG-purified fractions precipitated the esterasic activity, whereas they failed to precipitate the neuropeptide-hydrolyzing activities whatever the substrate examined. Altogether, these results demonstrate that peptidases associated with butyrylcholinesterase are contaminating enzymes that cannot be considered as intrinsic activities of this enzyme.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696618     DOI: 10.1111/j.1471-4159.1990.tb04555.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

1.  Monoclonal antibodies to human butyrylcholinesterase reactive with butyrylcholinesterase in animal plasma.

Authors:  Hong Peng; Stephen Brimijoin; Anna Hrabovska; Eric Krejci; Thomas A Blake; Rudolph C Johnson; Patrick Masson; Oksana Lockridge
Journal:  Chem Biol Interact       Date:  2015-11-14       Impact factor: 5.192

2.  Characterization of butyrylcholinesterase in bovine serum.

Authors:  Alicia J Dafferner; Sofya Lushchekina; Patrick Masson; Gaoping Xiao; Lawrence M Schopfer; Oksana Lockridge
Journal:  Chem Biol Interact       Date:  2017-02-08       Impact factor: 5.192

3.  Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease.

Authors:  C I Wright; C Guela; M M Mesulam
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

4.  Butyrylcholinesterase-Mediated enhancement of the enzymatic activity of trypsin.

Authors:  S Darvesh; R Kumar; S Roberts; R Walsh; E Martin
Journal:  Cell Mol Neurobiol       Date:  2001-06       Impact factor: 5.046

5.  Detection of cresyl phosphate-modified butyrylcholinesterase in human plasma for chemical exposure associated with aerotoxic syndrome.

Authors:  Lawrence M Schopfer; Patrick Masson; Patricia Lamourette; Stéphanie Simon; Oksana Lockridge
Journal:  Anal Biochem       Date:  2014-06-02       Impact factor: 3.365

6.  The peptidase activity of human serum butyrylcholinesterase: studies using monoclonal antibodies and characterization of the peptidase.

Authors:  R V Rao; A S Balasubramanian
Journal:  J Protein Chem       Date:  1993-02

7.  Comparison of 5 monoclonal antibodies for immunopurification of human butyrylcholinesterase on Dynabeads: KD values, binding pairs, and amino acid sequences.

Authors:  Hong Peng; Stephen Brimijoin; Anna Hrabovska; Katarina Targosova; Eric Krejci; Thomas A Blake; Rudolph C Johnson; Patrick Masson; Oksana Lockridge
Journal:  Chem Biol Interact       Date:  2015-09-03       Impact factor: 5.192

8.  A novel system for the efficient generation of antibodies following immunization of unique knockout mouse strains.

Authors:  Anna Hrabovska; Véronique Bernard; Eric Krejci
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

9.  Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.

Authors:  Herve Delacour; Sofya Lushchekina; Isabelle Mabboux; Aurore Bousquet; Franck Ceppa; Lawrence M Schopfer; Oksana Lockridge; Patrick Masson
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.